Study wrapper · #934
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Briand F, Le Cudennec C, Grasset E, et al. Obesity (Silver Spring, Md.). 2026.
DOI: 10.1002/oby.70155PubMed: 41741376
Editor's note
This is a preclinical study in diet-induced obese mouse and hamster models, so results are early and not human data. Retatrutide was associated with marked weight loss, lower HOMA-IR, and reduced hepatic triglycerides, though it did not improve liver histopathology scores. The work primarily validates the models for testing obesity and MASH therapies.
Plain-language abstract
In obese mouse and hamster models, retatrutide reduced body weight and was associated with improvements in insulin resistance, blood lipids, and liver fat content.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026